Prevalence of Creatinine Phosphokinase Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases

This study describes the elevation of CPK in patient treated for solid tumors by TKI

Completed

Looking for future studies?

Key information

Conditions

Cancer Muscular Diseases Musculoskeletal Diseases Musculoskeletal Pain Myalgia Neoplasms Nervous System Diseases Neurologic Manifestations Neuromuscular Diseases Pain Pathological Conditions, Signs and Symptoms Signs and Symptoms Solid Tumor

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Centre Paul Papin, Angers, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with solid tumor treated by inhibitor of tyrosin kinase for at least 1 week
Patient examined AND with a routine blood test planned
Patient informed of procedure for the study who was not opposed to it

Exclusion criteria

Patient treated for malignant hemopathy
Patient no treated by inhibitor of thyrosine kinase or for less than 1 week
Patients with no routine blood laboratory tests planned

Treatment and study plan

CPK dosage

Biological

CPK dosage during a blood sample realized at least one week after the begining of the treatment

Clinical exam

Other

Examination of the patient for myalgia, cramps, medical history and concomitant medication

Primary outcomes

To evaluate the prevalence of the CPK increase

Time frame: Within 3 days after a clinical exam

Dosage of CPK during standard blood sampling. The increase of CPK is defined when CPK value > USL

Secondary outcomes

Correlation myalgia/CPK increase

Time frame: During the clinical exam

To determine the correlation between myalgia and CPK blood, taking into account the risk factors leading to CPK increase

Sponsors and collaborators

Lead sponsor

Centre Oscar Lambret

Other

Registry information

Official study title

National Study of Prevalence of Creatinine Phosphokinase (CPK) Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases (TKI)

Acronym: TKI-CPK

Important dates

Study start: 2010
Primary completion: 2010
Study completion: 2013
First posted: Nov 25, 2010
Registry last updated: Mar 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed